Matches in Wikidata for { <http://www.wikidata.org/entity/Q86241743> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q86241743 description "clinical trial" @default.
- Q86241743 description "ensayu clínicu" @default.
- Q86241743 description "klinisch onderzoek" @default.
- Q86241743 description "клінічне випробування" @default.
- Q86241743 description "կլինիկական փորձարկում" @default.
- Q86241743 name "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241743 name "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241743 type Item @default.
- Q86241743 label "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241743 label "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241743 prefLabel "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241743 prefLabel "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241743 P1050 Q86241743-18AFCF5A-E986-41C6-8113-8A8DF3128A32 @default.
- Q86241743 P1050 Q86241743-52C48814-6DA5-454F-B1C0-6E3812701337 @default.
- Q86241743 P1132 Q86241743-AFBBAF0D-82BF-4190-BCCF-AF32ADFA817D @default.
- Q86241743 P1476 Q86241743-321EBC68-C2F8-4873-A1B3-B33F95A7FE6A @default.
- Q86241743 P1813 Q86241743-C45CF644-DB64-4B24-AB84-C3D0E510FA64 @default.
- Q86241743 P2899 Q86241743-FE131116-7884-4A9E-A43E-89EDFA0CC7BA @default.
- Q86241743 P3098 Q86241743-E0C6D523-DFDD-4A72-BB23-142AC17F095D @default.
- Q86241743 P31 Q86241743-12ED8B74-F23F-4266-843F-E9308BB78759 @default.
- Q86241743 P580 Q86241743-BC1C8E8B-B315-43DC-8B92-B91B26E418A2 @default.
- Q86241743 P582 Q86241743-3741DB3E-595A-4BFE-A5A9-2E8FC5406569 @default.
- Q86241743 P6099 Q86241743-E3CBBAD3-0AE6-4055-8664-5ACFFCB42831 @default.
- Q86241743 P8363 Q86241743-7B1D74D6-44F5-496B-A5A5-40EF68BBDDAF @default.
- Q86241743 P921 Q86241743-287899CA-4AAA-4F51-B020-A443ED386671 @default.
- Q86241743 P1050 Q2298953 @default.
- Q86241743 P1050 Q341999 @default.
- Q86241743 P1132 "+490" @default.
- Q86241743 P1476 "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa" @default.
- Q86241743 P1813 "BE HEARD I" @default.
- Q86241743 P2899 "+18" @default.
- Q86241743 P3098 "NCT04242446" @default.
- Q86241743 P31 Q30612 @default.
- Q86241743 P580 "2020-02-01T00:00:00Z" @default.
- Q86241743 P582 "2022-02-28T00:00:00Z" @default.
- Q86241743 P6099 Q42824827 @default.
- Q86241743 P8363 Q78089383 @default.
- Q86241743 P921 Q341999 @default.